SCHEMBL3080156

SCHEMBL3080156

CC(C)N(C(=O)C(Cc1ccc(NC(=O)c2ccccc2)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1)c1ccc(F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 6/20 0.49
ENPP3 O14638 1/20 0.44
ENPP1 P22413 1/20 0.44
MAPT P10636 3/20 0.44
LARS1 Q9P2J5 1/20 0.43
MMP9 P14780 1/20 0.42
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 3/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
F2 P00734 1/20 0.42
GPR27 Q9NS67 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
CASP3 P42574 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
KAT6A Q92794 1/20 0.40
OPRD1 P41143 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3096996 0.90 USP30 (0.46) USP30ENPP3ENPP1MAPTLARS1
SCHEMBL3101068 0.87 LARS1 (0.46) LARS1KMT2AMEN1F2KAT6A
SCHEMBL3090460 0.87 MMP9 (0.49) USP30MAPTLARS1MMP9KDM4E
SCHEMBL3103710 0.87 KAT6A (0.47) ENPP3ENPP1LARS1MMP9KMT2A
SCHEMBL3090637 0.87 RAB9A (0.48) USP30ENPP3ENPP1MAPTLARS1
SCHEMBL3097664 0.86 ALDH1A1 (0.46) USP30LARS1MMP9ALDH1A1KMT2A
SCHEMBL3103341 0.86 MMP9 (0.48) MAPTLARS1MMP9ALDH1A1KMT2A
SCHEMBL3087740 0.85 LARS1 (0.44) LARS1KMT2AMEN1F2KAT6A
SCHEMBL3102827 0.85 MEN1 (0.50) LARS1KMT2AMEN1LMNAF2
SCHEMBL3102970 0.85 MMP9 (0.46) LARS1MMP9ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 USP30 1341/4885ENPP3 1838/4885ENPP1 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.